Introduction
Regular surveillance of local antimicrobial susceptibility patterns is recommended, as it can provide information on new, or changing, patterns of resistance, and may be useful in informing clinician prescribing and choice of empiric therapy. The South African Society for Clinical Microbiology is a voluntary professional association, which is continuing the antimicrobial surveillance activities previously carried out by the National Antibiotic Surveillance Forum (NASF), and its predecessor organisations. Previous reports on bloodstream isolates identified in public sector laboratories, documented, among other findings, the markedly greater resistance in Klebsiella pneumoniae, compared to Escherichia coli, as well as a general upward trend in resistance in these two organisms between [2001] [2002] [2003] [2004] . 1 A report from 2007 suggested stabilisation of resistance levels, but figures from 2009 revealed increasing resistance to ciprofloxacin, and increased levels of extendedspectrum beta-lactamase (ESBL) production in K. pneumoniae, as well as high levels of methicillin-resistant Staphylococcus aureus (MRSA). 2, 3 Reports from South African private sector laboratories have highlighted similar concerns with MRSA and ESBL producers, as well as high levels of resistance in Pseudomonas aeruginosa and Acinetobacter baumannii. 4 Here we report on antimicrobial susceptibility surveillance data for six key bloodstream pathogens identified in public sector hospitals in South Africa during the 12 months between January-December 2010.
Methodology
Antimicrobial susceptibility testing was carried out on site by accredited National Health Laboratory Service (NHLS) laboratories. The following laboratories, located in different cities, participated in antimicrobial surveillance in 2010: Chris Hani Baragwanath (Johannesburg), Charlotte Maxeke Johannesburg Academic (Johannesburg), Steve Biko Academic (Pretoria), Universitas (Bloemfontein), Groote Schuur (Cape Town), Tygerberg (Cape Town), and Green Point NHLS laboratory (Cape Town).
Laboratories used a variety of testing methodologies (see Table I ), and interpreted results according to the contemporary 2010 Clinical and Laboratory Standards Institute (CLSI) criteria. 5 Data on final authorised results were transferred to the NHLS centralised data repository, Central Data Warehouse We report on antimicrobial susceptibility surveillance data for six key bloodstream pathogens (Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus) identified in public sector hospitals in South Africa during 2010. Major findings include the accelerated emergence of carbapenem resistance among K. pneumoniae and Enterobacter species, with overall susceptibility rates of 98% and 96% for ertapenem, and above 99% for meropenem and imipenem. Levels of resistance among P. aeruginosa and A. baumannii remain high in all centres, with few changes since 2009. Large decreases in piperacillin-tazobactam susceptibility rates were noted at three institutions, probably related to methodological issues. S. aureus remains a major pathogen countrywide, with between 30-60% of isolates resistant to cloxacillin [methicillin-resistant S. aureus (MRSA)]. Ongoing surveillance for antimicrobial resistance is vital, and the use of a centralised data extraction system may aid in this.
(CDW). Data for specified organisms, isolated from bloodstream infections, were extracted by computer programme from CDW on a quarterly, and annual, basis. Subsequently, the data extracts were reviewed by local pathologists to ensure consistency with local experience.
Guidelines on reporting of cumulative AST data were followed, in that susceptibility test results were omitted if a laboratory reported < 30 isolates per annum, or if selective testing was performed. For these reasons, 2010 data from Dr George Mukhari were excluded, as were data from Green Point NHLS laboratory for ESBL and carbapenem susceptibility testing, and for P. aeruginosa and A. baumannii. 6 However, because of computer software limitations, it was not possible to exclude duplicate isolates as recommended by the guidelines. 6 Results are reported as percentage susceptible, with 95% confidence intervals calculated by the Clopper-Pearson method. 6 Categorical data were analysed using a chi-square test. Specific data on ESBL production were not reliably reported, and hence ESBL production was inferred if E.coli and K. pneumoniae isolates were reported as resistant to cefepime. Since this inference is unreliable in Enterobacter spp., ESBL production is not reported for these isolates, but simply cefepime susceptibility rates.
Antimicrobial susceptibility results were reported for the following six organisms: E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa, A. baumannii and S. aureus. Communityacquired meningeal, respiratory, or diarrhoeal pathogens, that 7 The choice of antibiotics to be reported was determined by members of the NASF in 2009. The following criteria influenced their decisions: the antibiotic was included in routine susceptibility testing panels in most, if not all, laboratories; and the antibiotic was available in South Africa, and considered by local clinicians to be therapeutically useful.
Results
The antimicrobial susceptibilities of specified organisms are listed in Tables II-VII 
Escherichia coli
The susceptibility of E.coli isolates (see Table II , Figure 1 ) ranged from 80-88% for gentamicin, 82-97% for amikacin, and 82-92% for ciprofloxacin. However, these figures exclude results from Steve Biko Academic (Pretoria) where strains appear to be consistently less susceptible, with only 81% susceptible to gentamicin, 73% susceptible to amikacin, and 67% susceptible to ciprofloxacin. Similarly, 25% of Steve Biko Academic E.coli strains produce ESBLs, which confer resistance to broad-spectrum cephalosporins, compared to only 3-17% of strains from the other six laboratories. Minimal carbapenem resistance was reported among E. coli, with a single isolate from Chris Hani Baragwanath that was resistant to ertapenem and meropenem.
Klebsiella pneumoniae
Thirty to fifty-one per cent of K. pneumoniae isolates were susceptible to gentamicin (see Table III , Figure 2 ), and 49-79% were susceptible to ciprofloxacin. Susceptibility to amikacin ranged from 66-98%, while 55-74% of all strains produced ESBLs. Six of seven laboratories reported resistance to carbapenems. Ertapenem susceptibility rates ranged from 96-99%, and imipenem or meropenem susceptibility rates from 98-100%.
Enterobacter species
Reported susceptibility rates among Enterobacter spp. ranged from 55-87% for gentamicin (see Table IV , Figure 3 ), 84-93% for amikacin, and 75-92% for ciprofloxacin. Cefepime susceptibility varied from 58-86%. While no resistance to meropenem or imipenem was reported, susceptibility rates for ertapenem were 91-99%.
Pseudomonas aeruginosa
High levels of resistance to the various antipseudomonal antibiotics were reported from all laboratories, with no single antibiotic agent attaining more than 65% susceptibility countrywide (see Table V , Figure 4 ). Patterns of susceptibility varied considerably between different laboratories, with the highest levels of carbapenem resistance occurring in the Western Cape (55% susceptibility to imipenem and 55% and 67% susceptibility to meropenem, at Groote Schuur and Tygerberg, respectively). Extreme differences in piperacillin-tazobactam susceptibility rates were noted (from 1-80%).
Acinetobacter baumannii
High levels of resistance to all antibiotics were reported from all laboratories, though the number of isolates varied considerably (see Table VI, Figure 5 ). Surveillance Data: Antimicrobial susceptibility patterns of bacteraemic isolates from the South African public sector
Staphylococcus aureus
Between 41-76% of S. aureus isolates were susceptible to cloxacillin (see Table VII , Figure 6 ), while susceptibility to erythromycin and clindamycin was slightly higher, ranging from 41-83%, and from 55-85% respectively. S. aureus was one of the most common bloodstream pathogens, and constituted the largest number of isolates for any single organism at three out of seven laboratories, while in the remaining four sites, it was matched only by K. pneumoniae (in three laboratories) or K. pneumoniae and E.coli (in one laboratory). Note: Data from NHLS Universitas and Green Point, excluded, as the number of isolates was < 30. n = number susceptible, N = number tested, % = percentage susceptible, 95% CI = 95% confidence interval and they service predominantly, though not exclusively, tertiary referral hospital populations. Green Point laboratory serves predominantly primary level hospitals, and this is reflected in both the smaller numbers of the typical intensive care unit pathogens (P. aeruginosa and A. baumannii isolated) as well as in the lower levels of resistance reported, for example 76% of Green Point S. aureus isolates were susceptible to cloxacillin.
Discussion
The bloodstream isolates included in this report reflect a mixture of both community-and hospital-acquired infections, and the relative proportions may influence the antimicrobial susceptibility profiles. Thus E. coli bacteraemia, which frequently originates from the normal enteric flora in conditions such as community-acquired urinary tract infections or acute abdominal sepsis, may show higher levels of susceptibility than K. pneumoniae, a predominantly hospital-acquired pathogen. The very varied antimicrobial susceptibility profiles of P. aeruginosa from different laboratories probably reflects local nosocomial spread of endemic strains.
Compared to 2009, levels of resistance to gentamicin, amikacin, ciprofloxacin and cephalosporins, among E. coli, K. pneumoniae and Enterobacter spp., remained generally unchanged, apart from decreasing susceptibility reported from Steve Biko Academic. This decrease in susceptibility requires further investigation, to determine whether it represents a genuine increase in resistance, or whether it is an artifact, due to changes in laboratory techniques or catchment population. Nonetheless, the reported low levels of susceptibility, particularly to ciprofloxacin (67%), are reason for concern.
However, the major change noted in 2010 was the increased resistance to carbapenems among K. pneumoniae and Enterobacter species. Resistance to carbapenems was first noted in 2009, but is now far more widespread, with low levels of resistance reported from all laboratories. Resistance is greater for ertapenem, than imipenem or meropenem. Unfortunately, neither the minimum inhibitory concentration (MIC) values for these isolates, nor the mechanisms of carbapenem resistance, were available for reporting. While a combination of either ESBL or intrinsic AmpC-type cephalosporinase production, plus decreased permeability, is the most likely cause of carbapenem resistance, the presence of carbapenemases, such as New Delhi metallobeta-lactamase-1 (NDM-1), detected in Gauteng in 2011, or others, cannot be excluded. [8] [9] [10] [11] The impact of increasing carbapenem resistance, particularly in K. pneumoniae, is likely to be severe, as this organism is a common, multi-resistant, nosocomial pathogen, and there are few alternative treatment options available.
The levels of resistance to multiple antibiotics among P. aeruginosa and A. baumannii remain high in all laboratories, Note: Data from NHLS, Green Point, excluded, as the number of isolates was < 30. n = number susceptible, N = number tested, % = percentage susceptible, 95% CI = 95% confidence interval with few changes since 2009. However, at Steve Biko Academic, there were significant increases in susceptibility of P. aeruginosa to gentamicin, ciprofloxacin, cefepime, ceftazidime and meropenem in 2010 (p-value < 0.05). There was no significant change in imipenem susceptibility rates. The reasons for these changes are unknown, but it could possibly be due to decreased transmission of highly resistant hospitalacquired strains. Conversely, decreased rates of susceptibility were seen for gentamicin at Tygerberg and Charlotte Maxeke Johannesburg Academic laboratories (p-value < 0.05).
Large decreases in piperacillin-tazobactam susceptibility rates were noted at three institutions, with reductions from 60% to10% at Steve Biko Academic, from 40% to 1% at Groote Schuur, and from 43% to 27% at Tygerberg. All three laboratories perform antimicrobial susceptibility testing with the Vitek 2 ® system, an automated system, previously noted to have a high rate of false susceptibility results for testing of P. aeruginosa against piperacillin-tazobactam. 12 The dramatic increase in piperacillin-tazobactam resistance suggests that the system's Advanced Expert System may have been changed in 2010 to minimise false susceptibility reporting, but that this also had the effect of artificially inflating resistance rates. The Vitek 2 ® system is currently being reformulated to permit more accurate determination of piperacillintazobactam susceptibility in future.
The clinical significance of A. baumannii bacteraemia is more difficult to interpret, as on occasions, the presence of these low-virulence organisms may reflect contamination with colonising skin flora. Colistin susceptibility of A. baumannii is not reported here, partly because of problems with testing method standardisation. However, this important therapeutic antibiotic will be included in future surveillance.
S. aureus remains a major pathogen countrywide, with between 30-60% of isolates resistant to cloxacillin (MRSA). These figures are in agreement with the GERMS-SA data from sentinel site surveillance, which revealed MRSA bloodstream infection rates of between 41-46% for 2010. 7 
Limitations
While these national laboratory-based surveillance data provide valuable information, they are, in common with all laboratorybased surveillance data, subject to certain clinical and technical limitations. The major clinical limitation is the fact that the probability of detecting a bloodstream pathogen depends on the test request practices of clinicians. Thus the numbers and proportions of resistant or susceptible organisms may vary, depending on whether clinicians in different institutions are more or less likely to take blood cultures in particular clinical scenarios. In addition, laboratory surveillance data on their own cannot distinguish between community-acquired and hospitalacquired infections, and hence clinicians should be wary of direct extrapolation of these data to clinical practice. Other limitations are the retrospective nature of the data collection, delays in reporting, and lack of clinical correlation, although it can be assumed that the vast majority of bloodstream pathogens reported here are significant.
In addition, certain technical limitations may affect the presented data. Since it was not possible to retest all isolates at a central laboratory, the susceptibility data are completely dependent on the accuracy of laboratory practices in the participating institutions. Different laboratories utilise different testing systems (see Table I ), and there may also be differences in interpretation of certain borderline results. However, all laboratories are fully accredited and maintain high standards, as evidenced by participation in ongoing external qualityassurance programmes.
At the data collection level, extraction of data via CDW can eliminate potential variations in data collation that might occur when this is performed at local laboratory level. However, centralised data extraction also highlights differences in reporting practices between laboratories, for example use of different codes to report the same organism. While attempts have been made to correct such differences, undetected errors may still occur.
Most importantly, at this stage, CDW data extraction methods were not able to exclude duplicate isolates, a recommended 
Conclusion
Despite these limitations, we conclude that antimicrobial resistance in key pathogens is high, and that the threat of increasing resistance, particularly with regard to carbapenems, is real. Ongoing surveillance is essential, but data extraction methods need to be further refined, specifically to exclude duplicate isolates. Centralised data extraction is a valuable tool, because the standardised data it generates have the potential to facilitate further analysis of trends in antimicrobial resistance in a more timeous manner. Ideally antimicrobial resistance surveillance should be linked to increased capacity for further studies on highly resistant organisms, while studies that differentiate between community-acquired and hospitalacquired infections are also highly desirable.
